Comparative Pharmacology
Head-to-head clinical analysis: ZONISADE versus ZTALMY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZONISADE versus ZTALMY.
ZONISADE vs ZTALMY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Zonisamide is a sulfonamide anticonvulsant. Its precise mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels and reduce T-type calcium currents, thereby stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It may also modulate GABA and glutamate neurotransmission.
Ganaxolone is a positive allosteric modulator of GABAA receptors, acting at extrasynaptic and synaptic receptors to enhance chloride ion conductance and inhibit neuronal excitability.
100-200 mg orally every 8 hours; maximum 600 mg/day.
Initial: 5 mg orally once daily for 7 days; titrate by 5 mg/day every 7 days to a maintenance dose of 30 mg once daily. Maximum: 30 mg daily.
None Documented
None Documented
Terminal elimination half-life: 63-69 hours in adults; allows once-daily dosing; steady-state achieved in 14-21 days
Terminal elimination half-life is approximately 30 hours (range 20-40 hours) in adults, supporting once-daily dosing. Steady-state is achieved within 5-7 days.
Renal: approximately 62% (35% unchanged, 27% as glucuronide conjugate); fecal: 3%; biliary: negligible
Primarily hepatic metabolism via glucuronidation and oxidation; <1% excreted unchanged in urine. Fecal elimination accounts for approximately 90% of the administered dose, with <5% in urine.
Category C
Category C
Anticonvulsant
Anticonvulsant